Opportunity
University Of Central Arkansas Uark #IFB11162026
Automated solid-phase peptide synthesizer for University of Arkansas biomedical engineering research
Posted
November 17, 2026
Respond By
December 04, 2026
Identifier
IFB11162026
NAICS
334516
The University of Arkansas is seeking an automated peptide synthesizer for biomedical engineering research. - Government buyer: University of Arkansas, Fayetteville, Office of Business Affairs/Office of Procurement; Hwang Research Laboratory, Department of Biomedical Engineering, College of Engineering. - OEM/reference model: CEM — Liberty Blue 2.0. Equivalent systems may be proposed with documentation showing they meet the requirements. - Product: One fully automated solid-phase peptide synthesizer, including a PC, software, and starter reagent and amino-acid kits. - Key requirements: Controlled microwave heating from at least 25–110°C; four or more isolated reagent paths; support for common SPPS coupling chemistries, including DIC/Oxyma-based CarboMAX; synthesis across at least 5 μmol to 5 mmol using no more than two vessel sizes; and an upgrade path for a queue of at least 12 peptides. The system should support fast compatible cycles, avoid resin washing, use headspace flushing during deprotection, and produce less than 8 mL of waste per cycle at 0.1 mmol scale. - Services and support: Shipping, installation, system testing and verification, and initial user training. A minimum two-year warranty is required. - Term and delivery: Initial four-year contract term with three optional renewal years. In-stock equipment is required within 30 days after receipt of the purchase order; specialty items with longer standard lead times are exempt from that limit.
Description
The University of Arkansas is seeking bids for the purchase, delivery, installation, and commissioning of a fully automated solid-phase peptide synthesizer for the Hwang Research Laboratory in the Department of Biomedical Engineering. The instrument will support research-scale synthesis of diverse peptide sequences and modifications, including peptides used in biomaterials, nanomaterials, therapeutic delivery, and related biomedical research. Bids are due December 4, 2026, at 2:30 p.m. CST, and must be submitted through UA Formal Bid Submission.